Dow Jones Newswires: FDA panel rejects ALS treatment from Brainstorm Cell Therapeutics

A U.S. Food and Drug Administration advisory committee voted against a treatment from BrainStorm Cell Therapeutics for amyotrophic lateral sclerosis, or ALS.

Previous post : Sony Interactive Entertainment CEO Jim Ryan will retire in March
Next post What’s Worth Streaming: What’s new on Netflix in October 2023 — and what’s leaving